niacinamide and gsk2879552

niacinamide has been researched along with gsk2879552 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T1

Other Studies

1 other study(ies) available for niacinamide and gsk2879552

ArticleYear
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Cancer letters, 2017, 07-10, Volume: 398

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2017